Literature DB >> 9666776

Surgery as salvage therapy in chemotherapy-resistant nonseminomatous germ cell tumours.

R Ravi1, J Ong, R T Oliver, D F Badenoch, C G Fowler, W F Hendry.   

Abstract

OBJECTIVE: To review our experience of surgical staging for residual masses after chemotherapy in patients with nonseminomatous germ cell tumour (NSGCT) and positive tumour markers. PATIENTS AND METHODS: Of 107 patients with metastatic NSGCTs treated surgically after chemotherapy from 1978 to 1995, 30 (median age 30.5 years, range 20-52) had positive tumour markers. These patients were reviewed and the outcome compared with 77 patients who had normal tumour marker values.
RESULTS: Of the 77 patients with negative markers undergoing surgical/pathological staging, 71 (92%) became continuously disease-free, including 37 of 50 (74%) with viable NSGCT in excised specimens. Seventeen of 30 (57%) with raised marker levels undergoing similar surgery for chemotherapy-resistant tumour became disease-free, including 11 of 22 with viable NSGCT in the excised specimens.
CONCLUSION: Although the outcome after surgery is better in patients with negative tumour markers, it is clear that surgery is curative for patients with localized chemotherapy-resistant masses. There is a need for continued debate on the timing of salvage surgery and subsequent chemotherapy.

Entities:  

Mesh:

Year:  1998        PMID: 9666776     DOI: 10.1046/j.1464-410x.1998.00346.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  3 in total

Review 1.  Advances in the treatment of testicular cancer.

Authors:  Hans-Georg Kopp; Markus Kuczyk; Johannes Classen; Arnulf Stenzl; Lothar Kanz; Frank Mayer; Michael Bamberg; Jörg Thomas Hartmann
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 2.  Current controversies on the role of retroperitoneal lymphadenectomy for testicular cancer.

Authors:  Roy Mano; Renzo Di Natale; Joel Sheinfeld
Journal:  Urol Oncol       Date:  2018-11-13       Impact factor: 3.498

Review 3.  Surgical salvage in patients with advanced testicular cancer: indications, risks and outcomes.

Authors:  Ryan W Speir; Clint Cary; Timothy A Masterson
Journal:  Transl Androl Urol       Date:  2020-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.